At a glance
A small-molecule research tool for studying NNMT and cellular metabolism.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses metabolic and body-composition findings from experimental models. These observations should be separated from demonstrated benefits in people.[8][9][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of 5-Amino-1MQ.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 50 mg · 1 source tables
Subcutaneous Protocol (4 mL = 12.5 mg/mL)
| Phase | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Days 1–2 (Tolerance) | 2.5 mg once daily | 20 units (0.20 mL) |
| Days 3+ (Standard) | 5 mg once daily | 40 units (0.40 mL) |
| Alternative BID | 2.5 mg twice daily | 20 units (0.20 mL) × 2 |
Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours[5], twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 50 mg vial provides 10–20 days of research material at these doses.
Additional schedule context & duration
Concise summary of the subcutaneous regimen.
- Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels[1][2].
- Schedule: Daily subcutaneous injections; each 50 mg vial provides 10–20 days of research material.
- Dose Range: 2.5–5 mg once or twice daily.
- Reconstitution: 4.0 mL per 50 mg vial (12.5 mg/mL) for accurate measurements.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).
Suggested approach for the 50 mg vial format.
- Start: 2.5 mg once daily to assess tolerance.
- Target: 5 mg once daily or 2.5 mg twice daily (BID).
- Frequency: Once or twice per day (subcutaneous).
- Vial Duration: Single 50 mg vial lasts 10–20 days at research doses.
- Timing: Morning administration preferred; BID dosing may be split AM/PM.
Preparation
Reconstitution Steps
- Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
- Draw 4.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved—solution should be clear (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.
Storage Instructions
Proper storage preserves compound stability.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
- Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues.
- Do not refreeze reconstituted solution.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[6].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][13].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[7].
- Slow injection may minimize any stinging sensation associated with the compound.
Materials & quantity planning
Source materials checklist · 50 mg
Plan based on research duration using the 50 mg vial format at 5 mg/day.
- 5-Amino-1MQ Vials (50 mg each):
- 1 week (5 mg/day) ≈ 1 vial
- 2 weeks (5 mg/day) ≈ 1 vial
- 4 weeks (5 mg/day) ≈ 2 vials
- Insulin Syringes (U-100):
- Per week (once daily): 7 syringes
- Per week (BID): 14 syringes
- 4 weeks (once daily): 28 syringes
- Bacteriostatic Water (10 mL bottles): Use 4.0 mL per vial for reconstitution.
- 1 week (1 vial): 4 mL → 1 × 10 mL bottle
- 2 weeks (1 vial): 4 mL → 1 × 10 mL bottle
- 4 weeks (2 vials): 8 mL → 1 × 10 mL bottle
- Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- Per week (once daily): 14 swabs
- 4 weeks (once daily): 56 swabs → recommend 1 × 100-count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 50 mg per vial and 4 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
Nature Medicine (2014) — Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
PMC (2024) — Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Source document
Frontiers in Pharmacology (2024) — NNMT: a novel therapeutic target for metabolic syndrome (opens in a new tab)www.frontiersin.org
Back to overview ↑ - 04
Source document
Creative Peptides — Peptide stability and storage guidelines for lyophilized compounds (opens in a new tab)www.creative-peptides.com
Back to overview ↑ - 05
Research publication
PubMed (2021) — LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetic and oral bioavailability study (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
PMC — Subcutaneous drug injection review: pharmacologic considerations (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
PMC (2022) — Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Source document
Swolverine — 5-Amino-1MQ mechanism, benefits, stacking and cycling guide (opens in a new tab)swolverine.com
Back to overview ↑ - 12
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 13
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 15
Research publication
PMC — NNMT: a bad actor in fat makes good in liver (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.